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First report of FIP1L1-PDGFRa-positive eosinophi-
lic granulomatosis with polyangiitis
SIR, Eosinophilic granulomatosis with polyangiitis (EGPA,
ChurgStrauss syndrome) is a rare systemic ANCA-
associated vasculitis with a pathogenesis probably
mediated by Th2-polarized responses [1, 2]. Recently,
imatinib mesylate has proved effective in EGPA [3, 4],
suggesting a possible pathogenic role for tyrosine
kinases.
Tyrosine kinases encoded by fusion genes (e.g. FIP1L1-
PDGFR) are important in the pathogenesis of hypereosi-
nophilic syndrome (HES), whose clinical features are often
similar to those of EGPA. The FIP1L1-PDGFRa fusion
gene, when found, is considered to rule out EGPA while
supporting a diagnosis of primary HES [5]. Here, we
describe the first case of a patient with EGPA carrying
the FIP1L1-PDGFR rearrangement and discuss whether
this finding is relevant in the differential diagnosis between
HES and EGPA.
A 41-year-old woman was admitted to our unit for fever
and severe asthma. One month earlier she had been diag-
nosed with EGPA in a neurology unit because she had
mononeuritis multiplex with wrist and foot drop, asthma,
nasal polyposis and rhinosinusitis, bloody diarrhoea,
peripheral eosinophilia and P-ANCA positivity, which
tested anti-MPO by ELISA (>100 EU/ml, normal <10).
Endoscopy had revealed gastric erosions, with histolo-
gical evidence of eosinophil-rich inflammation of the
lamina propria (Fig. 1A). The patient received a pulse of
6-methylprednisolone (125 mg/day for 3 days), followed
by oral prednisone and i.v. immunoglobulins (400 mg/kg/
day for 5 days), with good clinical response. The off-label
treatment with rituximab was approved by the AOU
Careggi Hospital ethics committee, and informed consent
was obtained.
On admission to our unit, she was taking 10 mg/day
prednisone; laboratory tests showed persistent eosino-
philia (5590/mm3) and mild anaemia (haemoglobin
10.2 g/dl). MPOANCA positivity was confirmed. Given
the persistence of eosinophilia despite ongoing steroid
therapy, bone marrow biopsy was also performed, and
showed mild eosinophilic hyperplasia, without atypias
(Fig. 1B). Moreover, we searched for FIP1L1-PDGFR
using a nested RT-PCR and for FIP1L1-PDGFR and -
FGFR1 fusion genes using FISH. This analysis revealed
the presence of the FIP1L1-PDGFR rearrangement
(Fig. 1C; patient characteristics and details of the genetic
analysis are reported in supplementary Table S1, available
at Rheumatology Online).
The patient resumed 1 mg/kg/day prednisone, which
induced symptom remission; however, epigastric pain,
myalgia, neuropathy and blood hypereosinophilia flared
when prednisone was tapered below 20 mg/day.
Therefore, we added rituximab (1000 mg on days 0 and
15). The patient had a rapid clinical response, and the
eosinophil count also normalized. Six months later, while
taking 5 mg/day prednisone, she was asymptomatic, with
a normal eosinophil count.
To the best of our knowledge, the FIP1L1-PDGFR
fusion gene has never been described in EGPA. To
assess the frequency of this finding in EGPA, we con-
ducted an exploratory analysis of the FIP1L1-PDGFR
fusion gene in 11 additional consecutive patients with
systemic EGPA (detailed data are reported in supplemen-
tary Table S1, available at Rheumatology Online), all
of whom tested negative. Nevertheless, we believe that
our finding has potential pathogenic and clinical implica-
tions. Together with previous reports showing the efficacy
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of imatinib in EGPA [3, 4], it highlights the possible role
of tyrosine kinases in EGPA pathogenesis. The exact
mechanisms through which such kinases drive eosino-
philia are still unclear [6]. Also, the presence of a
FIP1L1-PDGFRa rearrangement cannot be considered
an exclusive hallmark of HES/chronic eosinophilic leukae-
mia, and it may fail in distinguishing such conditions from
EGPA. Finally, the presence of such a fusion gene in
EGPA could help to identify an albeit very small proportion
of patients who theoretically benefit from tyrosine-kinase
inhibitors.
Given the severe disease presentation, our patient
would probably have warranted a combined treatment
with glucocorticoids and immunosuppressants, whereas
she received only glucocorticoids. Upon disease relapse,
we decided to use rituximab rather than CYC essentially
because of the young age of the patient. The excellent
response we observed is in line with recent reports
demonstrating the efficacy of rituximab in refractory
EGPA [7, 8]; interestingly, rituximab in EGPA has been
shown to reduce the production of IL-5, probably by
inhibiting B- to T-cell crosstalk [8].
FIG. 1 Histological findings and Sanger sequencing image
(A) Gastric biopsy: an eosinophil-rich inflammatory infiltrate is observed in the lamina propria (haematoxylin and eosin,
40). (B) Bone marrow biopsy: mild hyperplasia of the eosinophilic granulocyte series, without atypias; the other cellular
lineages are normal (haematoxylin and eosin, 40). (C) Sanger sequencing image of the patient (#1) who carried the
FIP1L1-PDGFR rearrangement.
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. The FIP1L1-PDGFR fusion gene, previously
thought to be positive only in hypereosinophilic syn-
dromes, can also be found in eosinophilic granulo-
matosis with polyangiitis.
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Comment on: Benefits and risks of low-dose
glucocorticoid treatment in the patient with
rheumatoid arthritis
SIR, The recently reported review [1] in this journal, though
interesting, does not appear to do full justice to the title on
the cover ‘New approaches to glucocorticoid treatment
for rheumatoid arthritis’ and in fact fails to add substan-
tially to what is already known on this subject. For
example, the effect of glucocorticoids on radiological pro-
gression in RA has already been appraised [2], as have
their clinical benefits and safety [3, 4]. Methodologically,
the authors appear to have conducted a systematic
review; however, their reporting is inadequate [5]. For ex-
ample, the present review is marked by the absence of a
flow diagram of studies, lack of sufficient information on
the method of data collection, measures to ascertain the
missing data in the studies and bias, the absence of qual-
ity assessment of the included studies, and a lack of dis-
cussion on the limitations at the study and outcome level.
These and several other lacunae [5] prevent a reader from
drawing any meaningful conclusions, and establish
generalizability.
Deflazacort is the only glucocorticoid derivative that,
despite its initial hype, is still widely used (though only in
a few countries, including India, Spain and Mexico); it,
therefore, deserves a fuller appraisal [6]. The popularly
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